“Keep investing in expanding manufacturing capacity is our commitment to customers”

Responding to the increased demand for products that are used in emerging modalities such as gene therapy, and are currently in high demand for the manufacture of COVID-19 vaccines and therapies, Cytiva is investing $1.5 billion over two years to meet growing demand for biotechnology solutions.

- Ankit Kankar

Francis Van Parys, Vice President, Asia Pacific, Cytiva, South Korea

Investment follows five strategic acquisitions made by the companies this year and is in addition to Cytiva’s continuing capacity investments estimated at $500 million through 2022. With this announcement, Cytiva is enhancing the global supply chain so customers in Asia Pacific region should feel the benefit. Francis Van Parys, Vice President, Asia Pacific, Cytiva, South Korea reveals more during a conversation with BioSpectrum Asia. Edited excerpts;

What are the new initiatives being planned for the APAC market? Are there any launches or announcements in the pipeline in 2021?

I would love to share our latest ongoing strategic growth plan - Cytiva and Pall Corporation will expand manufacturing capacity and services across geographies for global life sciences customers. The investment, already underway, includes new sites, expansion at existing factories, and is additional to previously announced investments. It follows five acquisitions made by the companies so far this year. This investment also addresses some of the key challenges highlighted in the Global Biopharma Resilience Index, conducted by Longitude, a Financial Times company, and published by Cytiva in March 2021. These include hiring and training talent, R&D collaboration, supply chain resilience, manufacturing models, as well as government policy and regulation.